Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis

European Archives of Psychiatry and Clinical Neuroscience

Volumn 264, Issue 1, 2014, Pages 17-25

  Müller, Hendrik ^a   Laier, Sonja ^b   Bechdolf, Andreas ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Clinical high risk, CHR; Cognitive behavioral therapy, CBT; Family therapy; First episode psychosis, FEP; Psychotherapy; Review; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OMEGA 3 FATTY ACID;

COGNITIVE THERAPY; EARLY INTERVENTION; EVIDENCE BASED PRACTICE; FAMILY THERAPY; GERMANY; HUMAN; NEGATIVE SYNDROME; OUTPATIENT CARE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOTHERAPY; REVIEW; SOCIAL ADAPTATION; EVIDENCE BASED MEDICINE; PROCEDURES; PSYCHOLOGY; PSYCHOTIC DISORDERS;

EVIDENCE-BASED MEDICINE; HUMANS; PSYCHOTHERAPY; PSYCHOTIC DISORDERS;

EID: 84921938420     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-014-0538-0     Document Type: Review

References (105)

1. Whiteford HA, Degenhardt L, Rehm J et al (2013) Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 382:1575–1586
2. Konnopka A, Klingberg S, Wittorf A et al (2009) [The cost of schizophrenia in Germany: a systematic review of the literature]. Psychiatr Prax 36:211–218
3. van Os J, Kapur S (2009) Schizophrenia. Lancet 374:635–645
4. Adams EK, Breen N, Joski PJ (2007) Impact of the National Breast and Cervical Cancer Early Detection Program on mammography and Pap test utilization among white, Hispanic, and African American women: 1996–2000. Cancer 109:348–358
5. Peters AL, Davidson MB, Schriger DL et al (1996) A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the diagnosis of diabetes using glycated hemoglobin levels. J Am Med Assoc 276:1246–1252
6. Psaty BM, Lumley T, Furberg CD et al (2003) Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. J Am Med Assoc 289:2534–2544
7. Häfner H, Riecher-Rossler A, Maurer K et al (1992) First onset and early symptomatology of schizophrenia. A chapter of epidemiological and neurobiological research into age and sex differences. Eur Arch Psychiatry Clin Neurosci 242:109–118
8. Häfner H, Maurer K, An der Heiden W (2013) ABC Schizophrenia study: an overview of results since 1996. Soc Psychiatry Psychiatr Epidemiol 48:1021–1031
9. Fusar-Poli P, Borgwardt S, Bechdolf A et al (2013) the psychosis high-risk state a comprehensive state-of-the-art review psychosis high-risk state. JAMA Psychiatry 70:107–120
10. Marshall M, Lewis S, Lockwood A et al (2005) Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry 62:975–983
11. Archer T, Karilampi U, Ricci S et al (2014) Neurotoxic vulnerability underlying schizophrenia spectrum disorders. Handbook of neurotoxicity, p 2181–2205. doi:10.1007/978-1-4614-5836-4_119
12. Schultze-Lutter F, Ruhrmann S, Fusar-Poli P et al (2012) Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des 18:351–357
13. Yung AR, Phillips LJ, Yuen HP et al (2003) Psychosis prediction: 12-month follow up of a high-risk (“prodromal”) group. Schizophr Res 60:21–32
14. Broome MR, Woolley JB, Johns LC et al (2005) Outreach and support in south London (OASIS): implementation of a clinical service for prodromal psychosis and the at risk mental state. Eur Psychiatry 20:372–378
15. Carr V, Halpin S, Lau N et al (2000) A risk factor screening and assessment protocol for schizophrenia and related psychosis. Aust N Z J Psychiatry 34(Suppl):S170–S180
16. Cornblatt BA, Lencz T, Smith CW et al (2003) The schizophrenia prodrome revisited: a neurodevelopmental perspective. Schizophr Bull 29:633–651
17. McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799
18. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251
19. Simon AE, Dvorsky DN, Boesch J et al (2006) Defining subjects at risk for psychosis: a comparison of two approaches. Schizophr Res 81:83–90
20. Yung AR, Stanford C, Cosgrave E et al (2006) Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res 84:57–66
21. Schultze-Lutter F (2009) Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 35:5–8
22. Klosterkotter J, Hellmich M, Steinmeyer EM et al (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164
23. Fusar-Poli P, Bonoldi I, Yung AR et al (2011) Predicting psychosis: a meta-analysis of evidence. Arch Gen Psychiatry. doi:10.1001/archgenpsychiatry.2011.1472
24. Fusar-Poli P, Nelson B, Valmaggia L et al (2014) Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 40:120–131
25. Addington J, Penn D, Woods SW et al (2008) Social functioning in individuals at clinical high risk for psychosis. Schizophr Res 99:119–124
26. Bechdolf A, Pukrop R, Kohn D et al (2005) Subjective quality of life in subjects at risk for a first episode of psychosis: a comparison with first episode schizophrenia patients and healthy controls. Schizophr Res 79:137–143
27. Lencz T, Smith CW, Auther A et al (2004) Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. Schizophr Res 68:37–48
28. Velthorst E, Nieman DH, Linszen D et al (2010) Disability in people clinically at high risk of psychosis. Br J Psychiatry 197:278–284
29. Addington J, Cornblatt BA, Cadenhead KS et al (2011) At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry 168:800
30. Ziermans TB, Schothorst PF, Sprong M et al (2011) Transition and remission in adolescents at ultra-high risk for psychosis. Schizophr Res 126:58–64
31. Fusar-Poli P, Deste G, Smieskova R et al (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69:562–571
32. Giuliano JA, Li H, Mesholam-Gately IR et al (2012) Neurocognition in the psychosis risk syndrome: a quantitative and qualitative review. Curr Pharm Des 18:399–415
33. Phillips LJ, Velakoulis D, Pantelis C et al (2002) Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr Res 58:145–158
34. Velakoulis D, Wood SJ, Wong MT et al (2006) Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry 63:139–149
35. Yücel M, Wood SJ, Phillips LJ et al (2003) Morphology of the anterior cingulate cortex in young men at ultra-high risk of developing a psychotic illness. Br J Psychiatry 182:518–524
36. Stone JM, Day F, Tsagaraki H et al (2009) Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol Psychiatry 66:533–539
37. Fusar-Poli P, Howes O, Allen P et al (2009) Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 16:67–75
38. Fusar-Poli P, Howes OD, Allen P et al (2010) Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 67:683–691
39. Fusar-Poli P, Stone JM, Broome MR et al (2011) Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 68:881–890
40. McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799
41. McGorry P, Nelson B, Phillips L et al (2012) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry. doi:10.4088/JCP.12m07785
42. McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928
43. Amminger GP, Schafer MR, Papageorgiou K et al (2010) Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 67:146–154
44. Addington J, Epstein I, Liu L et al (2011) A randomized controlled trial of cognitive behavioral therapy for individuals at clinical high risk of psychosis. Schizophr Res 125:54–61
45. Morrison AP, French P, Stewart SL et al (2012) Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 344:e2233
46. Morrison AP, French P, Walford L et al (2004) Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry 185:291–297
47. van der Gaag M, Nieman DH, Rietdijk J et al (2012) Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull 38:1180–1188
48. Bechdolf A, Wagner M, Ruhrmann S et al (2012) Preventing progression to first-episode psychosis in early initial prodromal states. Br J Psychiatry 200:22–29
49. Nordentoft M, Thorup A, Petersen L et al (2006) Transition rates from schizotypal disorder to psychotic disorder for first-contact patients included in the OPUS trial. A randomized clinical trial of integrated treatment and standard treatment. Schizophr Res 83:29–40
50. Miklowitz DJ, O’Brien MP, Schlosser DA et al (2014) Family-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trial. J Am Acad Child Adolesc Psychiatry. doi:10.1016/j.jaac.2014.04.020
51. Hutton P, Taylor PJ (2013) Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. Psychol Med 1–20. doi:10.1017/S0033291713000354
52. van der Gaag M, Smit F, Bechdolf A et al (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149:56–62
53. Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145–153
54. Angermeyer MC, Matschinger H, Schomerus G (2013) Attitudes towards psychiatric treatment and people with mental illness: changes over two decades. Br J Psychiatry 203:146–151
55. Lauber C, Nordt C, Falcato L et al (2001) Lay recommendations on how to treat mental disorders. Soc Psychiatry Psychiatr Epidemiol 36:553–556
56. Morrison AP, Birchwood M, Pyle M et al (2013) Impact of cognitive therapy on internalised stigma in people with at-risk mental states. Br J Psychiatry 203:140–145
57. Association AP (2006) American Psychiatric Association Practice Guidelines for the treatment of psychiatric disorders: compendium 2006. Am Psychiatric Pub, Washington
58. Birchwood M, Fiorillo A (2000) The critical period for early intervention. Psychiatric Rehabil Skills 4:182–198
59. Boonstra N, Klaassen R, Sytema S et al (2012) Duration of untreated psychosis and negative symptoms—a systematic review and meta-analysis of individual patient data. Schizophr Res. doi:10.1016/j.schres.2012.08.017
60. Barnes TR, Leeson VC, Mutsatsa SH et al (2008) Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. Br J Psychiatry 193:203–209
61. Perkins DO, Gu H, Boteva K et al (2005) Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 162:1785–1804
62. Harrigan SM, McGorry P, Krstev H (2003) Does treatment delay in first-episode psychosis really matter? Psychol Med 33:97–110
63. Penttilä M, Jääskeläinen E, Hirvonen N et al (2014) Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. Br J Psychiatry 205:88–94
64. Addington J, Leriger E, Addington D (2003) Symptom outcome 1 year after admission to an early psychosis program. Can J Psychiatry 48:204–207
65. Lieberman JA, Phillips M, Gu H et al (2003) Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. doi:10.1038/sj.npp.1300157
66. Coldham E, Addington J, Addington D (2002) Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 106:286–290
67. Schennach-Wolff R, Jäger M, Seemüller F et al (2009) Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res 43:1294–1301
68. Robinson D, Woerner MG, Alvir JMJ et al (1999) Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 56:241–247
69. Watt DC, Katz K, Shepherd M (1983) The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychol Med 13:663–670
70. Melle I, Johannesen J, Friis S et al (2006) Early detection of the first episode of schizophrenia and suicidal behavior. Am J Psychiatry 163:800–804
71. Birchwood M (2003) Pathways to emotional dysfunction in first-episode psychosis. Br J Psychiatry 182:373–375
72. Wisdom JP, Manuel JI, Drake RE (2011) Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment. Psychiatric Serv 62:1007–1012
73. Bechdolf PDA, Pohlmann B, Güttgemanns J et al (2012) Motivationsbehandlung für Patienten mit der Doppeldiagnose Psychose und Sucht. Der Nervenarzt 83:888–896
74. Elkins K, Hinton M, Edwards J (2004) Cannabis and psychosis: a psychological intervention. In: Gleeson JFM, McGorry PD (eds) Psychological interventions in early psychosis. Wiley, Chichester, p 137–156. ISBN: 0470020636, 9780470020630
75. Meister K, Burlon M, Rietschel L et al (2010) Psychose und Sucht bei Jugendlichen und Jungerwachsenen BR Teil 1: Prävalenz und Erklärungsmodelle. Fortschritte der Neurologie Psychiatrie 78:81–89
76. Álvarez-Jiménez M, Parker AG, Hetrick SE et al (2011) Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 37:619–630
77. Bird V, Premkumar P, Kendall T et al (2010) Early intervention services, cognitive–behavioural therapy and family intervention in early psychosis: systematic review. Br J Psychiatry 197:350–356
78. Marshall M, Rathbone J (2011) Early intervention for psychosis. Cochrane Database Syst Rev CD004718. doi:10.1002/14651858.CD004718.pub3
79. Nuechterlein KH, Dawson ME (1984) A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 10:300–312
80. Larsen TK, Bechdolf A, Birchwood M (2003) The concept of schizophrenia and phase-specific treatment: cognitive-behavioral treatment in pre-psychosis and in nonresponders. J Am Acad Psychoanal Dyn Psychiatry 31:209–228
81. Garety PA, Kuipers E, Fowler D et al (2001) A cognitive model of the positive symptoms of psychosis. Psychol Med 31:189–195
82. Cantor-Graae E, Selten JP (2005) Schizophrenia and migration: a meta-analysis and review. Am J Psychiatry 162:12–24
83. Matheson SL, Shepherd AM, Pinchbeck RM et al (2013) Childhood adversity in schizophrenia: a systematic meta-analysis. Psychol Med 43:225–238
84. de Sousa P, Varese F, Sellwood W et al (2013) Parental communication and psychosis: a meta-analysis. Schizophr Bull. doi:10.1093/schbul/sbt088
85. Kesting M-L, Lincoln TM (2013) The relevance of self-esteem and self-schemas to persecutory delusions: a systematic review. Compr Psychiatry. doi:10.1016/j.comppsych.2013.03.002
86. Fine C, Gardner M, Craigie J et al (2007) Hopping, skipping or jumping to conclusions? Clarifying the role of the JTC bias in delusions. Cogn Neuropsychiatr 12:46–77
87. Morris EMJ, Johns LC, Oliver JE (2013) Acceptance and commitment therapy and mindfulness for psychosis. Wiley, London
88. Kingdon DG, Turkington D (2005) Cognitive therapy of schizophrenia [electronic resource]. Guilford Publications, Incorporated, New York
89. Lieberman JA, Fenton WS (2000) Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 157:1727–1730
90. Henry L (2002) Cognitively oriented psychotherapy for first episode psychosis (COPE): a practitioner’s manual: early psychosis prevention and intervention centre. ISBN: 192071801X
91. Herrmann-Doig T, Maude D, Edwards J (2002) Systematic Treatment of Persistent Psychosis (STOPP): a psychological approach to facilitating recovery in young people with first-episode psychosis. Taylor & Francis, London
92. French P, Morrison AP (2004) Early detection and cognitive therapy for people at high risk of developing psychosis: a treatment approach. Wiley, London
93. Müller H, Bechdolf A (2013) Ist eine Behandlung mit Antipsychotika gerechtfertigt? InFo Neurologie & Psychiatrie 15:38–42
94. McGlashan TH, Levy ST, Carpenter WT Jr (1975) Integration and sealing over: clinically distinct recovery styles from schizophrenia. Arch Gen Psychiatry 32:1269
95. Gleeson JFM, McGorry PD (2004) Psychological interventions in early psychosis: a treatment handbook. Wiley, London
96. Taylor SE (1983) Adjustment to threatening events: a theory of cognitive adaptation. Am Psychol 38:1161
97. Fusar-Poli P, Yung A (2011) Should attenuated psychosis syndrome be included in the DSM5? The debate. Lancet. doi:10.1016/S0140-6736(11)61507-9
98. Häfner HBA, Klosterkötter J, Maurer K (2012) Psychosen - Früherkennung und Frühintervention. Der Praxisleitfaden. Schattauer, Stuttgart
99. Commonwealth of Australia (2012) A ten year roadmap for national mental health. http://www.health.gov.au/internet/publications/publishing.nsf/Content/mental-pubs-t-roadmap-toc
100. Birchwood M, Connor C, Lester H et al (2013) Reducing duration of untreated psychosis: care pathways to early intervention in psychosis services. Br J Psychiatry 203:58–64
101. NICE. National Institute for Health and Clinical Excellence Schizophrenia (2009) Core interventions in the treatment and management of schizophrenia in primary and secondary care (update). National Institute for Health and Clinical Excellence, London
102. Phillips LJ, Cotton S, Mihalopoulos C et al (2009) Cost implications of specific and non-specific treatment for young persons at ultra high risk of developing a first episode of psychosis. Early Interv Psychiatry 3:28–34
103. Valmaggia LR, McCrone P, Knapp M et al (2009) Economic impact of early intervention in people at high risk of psychosis. Psychol Med 39:1617–1626
104. Bechdolf A, Muller H, Stutzer H et al (2011) Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. Schizophr Bull 37(Suppl 2):S111–S121
105. Häfner H, Bechdolf A, Klosterkötter J et al. Psychosen - Früherkennung und Frühintervention: Der Praxisleitfaden: Schattauer; 2012